Mood drug inhibits breast cancer medication: study

Feb 08, 2010

A common antidepressant weakens or cancels the beneficial effects of a standard treatment for breast cancer, according to a study released Tuesday.

Women who take the mood drug paroxetine -- better known by its brand names Paxil and Seroxat -- at the same time as the breast cancer medication tamoxifen face an increased risk of death, researchers reported.

The antidepressant alone has no impact on the course of the disease but should not be taken at the same time as anti-cancer drug, the study recommended.

Tamoxifen significantly improves survival for the dominant type of breast cancer, the most commonly diagnosed cancer in women worldwide.

But to work properly, it must be converted by the liver into an active metabolite, the chemical that remains after a drug is broken down by the body.

It was previously suspected that antidepressants that boost the release of the naturally occurring neurotransmitter serotonin, such as paroxetine, might interfere with this process.

To find out, Catherine Kelly and colleagues at the Institute for Clinical Evaluative Sciences in Toronto, Canada investigated the health care records of 2,430 women with breast cancer who had received tamoxifen from 1993 to 2005.

About 30 percent of these women also received an antidepressant -- paroxetine more than any other -- at the same time, often prescribed over long periods to help patients cope with the stress of battling the deadly disease.

The use of paroxetine in combination with tamoxifen resulted in an increased long-term risk of breast cancer death -- approximately one additional fatality after five years of illness for every 20 women treated.

"These results highlight a drug interaction that is extremely common, widely underappreciated and potentially life-threatening, yet uniformly avoidable," said David Juurlink, a co-author or the study.

is prescribed to women who have so-called estrogen-receptor positive , which accounts for up to 80 percent of all cases of the disease.

Explore further: Blood and saliva tests help predict return of HPV-linked oral cancers

add to favorites email to friend print save as pdf

Related Stories

Some antidepressants may risk breast cancer return

May 31, 2009

(AP) -- Breast cancer survivors risk having their disease come back if they use certain antidepressants while also taking the cancer prevention drug tamoxifen, worrisome new research shows.

Researchers: tamoxifen's power comes from endoxifen

Dec 11, 2008

Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in ...

Adding radiation decreases breast cancer recurrence

Jan 22, 2007

Radiotherapy after breast conserving surgery for breast cancer reduces recurrence and prevents development of additional breast tumors in older women with early stage breast disease, according to a new study. Published in ...

Recommended for you

New paper describes how DNA avoids damage from UV light

8 hours ago

In the same week that the U.S. surgeon general issued a 101-page report about the dangers of skin cancer, researchers at Montana State University published a paper breaking new ground on how DNA – the genetic code in every ...

Drug target identified for common childhood blood cancer

9 hours ago

In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified ...

User comments : 0